AzTrials
AzTrials

E03.155.253NCT06232980

The Use of Sedation Score and Bispectral Index for Induction in Geriatric Patients

A study testing urological surgical intervention in people with E03.155.253 and Bispectral Index Monitor, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main objective of this clinical study is to determine the effectiveness of BIS-guided propofol administration in avoiding hypotension during propofol induction in geriatric patients. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
E03.155.253, Bispectral Index Monitor, Hypotension
What is being tested?
urological surgical intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
134 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Sep 2023to 15 Apr 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • T.R. Patients aged 65 and over who will undergo elective surgery under general anesthesia in the Urology Operating Room of the Ministry of Health Ankara City Hospital

Who cannot join

  • Being under 65 years old
  • Those who do not have the ability to read, understand and sign the consent form
  • Hemodynamically unstable patients
  • Those who have contraindications to anesthetic drugs
  • Patients who do not want to participate in the study
  • Patients with advanced dementia
  • Emergency surgical procedures

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara Bilkent City Hospital

    Ankara, Çankaya, 06530

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of Observer Alertness/Sedation Score (OAA/S) and Bispectral Index (BIS) Parameters for Induction of General Anesthesia With Propofol in Geriatric Patients

The main objective of this clinical study is to determine the effectiveness of BIS-guided propofol administration in avoiding hypotension during propofol induction in geriatric patients. The primary question it aims to answer is whether the mean arterial pressure can be maintained above 60mmHg with BIS-guided propofol induction. For this purpose, the observer's alertness sedation score will be compared with bispectral index-guided inductions.

Read the detailed description

The primary aim of this study is to determine the effectiveness of BIS-guided propofol administration to avoid hypotension in propofol induction in geriatric patients. Mean arterial pressure (MAP) below 60 mmHg is defined as hypotension. The secondary aims include finding the differences between the entry MAP and the MAP at each measurement, determining the difference between the entry MAP and the lowest MAP, determining the ratio of hypotensive and normotensive MAP measurements, determining the number of patients with severe hypotension (MAP<50 mmHg), determining the number of patients receiving vasopressor therapy and drug dosage, determining the number of patients who underwent Trendelenburg, and those who developed tachycardia (HR>100/min), determining the number of patients who developed hypertension (MAP>140), and finding the correlation between BIS values and MAP. T.R. In the Ministry of Health Ankara City Hospital Urology Operating Room, general anesthesia will be applied, and ventilation will be provided with LMA as two different approaches for patients over 65 years of age; By evaluating OAA/S-based propofol induction and BIS-guided propofol inductions, the investigators aim to investigate whether the use of BIS reduces the risk of developing hypotension by reducing the propofol dose in anesthesia induction. T.R. After receiving ethics committee approval at the Ministry of Health Ankara City Hospital Urology Operating Room, 122 patients over the age of 65 who will receive general anesthesia and ventilation with a laryngeal mask (LMA) under elective conditions will be included in the study.

The study will be designed as a prospective randomized controlled trial. A total of 122 patients undergoing elective surgery in the urology operating room will be divided into two groups, Group O and Group B, using computer-assisted randomization. Group O will undergo an anesthesia induction guided by OAA/S, while Group B will undergo a general anesthesia induction guided by BIS.

After being admitted to the operating room, Group O will have recorded heart rate (HR) in beats per minute, systolic arterial blood pressure (SAB) in mmHg, diastolic arterial blood pressure (DAB) in mmHg, mean arterial blood pressure (OAB) in mmHg, peripheral oxygen saturation (SpO2), and BIS values. Four milliliters per kilogram of appropriate balanced crystalloid solution will be administered 2 minutes after the start, and HR, SAB, DAB, OAB, SpO2, and BIS values will be reevaluated. These values will be recorded every 2 minutes for 14 minutes. Premedication will not be administered, and anesthesia induction will begin with 1 mcg/kg fentanyl. Many commonly used anesthesia induction agents, including propofol, can cause significant and even life-threatening drops in blood pressure, respiratory depression, and other adverse events. The dose ranges of propofol decrease with age, leading to the FDA's recommendation to reduce the induction dose from 2-2.5 mg/kg in geriatric patients to 1-1.5 mg/kg. In the clinic, a standard initial dose of 1.5 mg/kg of propofol and an infusion rate of 100 mg/min are applied in geriatric patients. The initial dose for both groups will be 1.5 mg/kg, and the infusion rate will be 100 mg/min. An additional 20 mg of propofol will be administered every 30 seconds until the Observer's Assessment of Alertness/Sedation (OAA/S) score is 1. In case of hypotension, the management of hypotension (vasopressor treatment, Trendelenburg position, fluid loading) is left to the discretion of the responsible anesthesiologist. Anesthesia maintenance will be provided with volatile anesthetics. At the end of the procedure, hemodynamic parameters (SAB, DAB, OAB, HR, SpO2), BIS values, Observer's Assessment of Alertness/Sedation Scale (OASS), time to reach OAA/S 1, anesthesia induction drug and doses, hypotension treatment, and airway equipment placement time will be recorded.

Upon admission to the operating room, Group B will have recorded heart rate (HR) in beats per minute, systolic arterial blood pressure (SAB) in mmHg, diastolic arterial blood pressure (DAB) in mmHg, mean arterial blood pressure (OAB) in mmHg, peripheral oxygen saturation (SpO2), and BIS values. Four milliliters per kilogram of appropriate balanced crystalloid solution will be administered 2 minutes after the start, and HR, SAB, DAB, OAB, SpO2, and BIS values will be reevaluated. These values will be recorded every 2 minutes for 14 minutes. Premedication will not be administered, and anesthesia induction will begin with 1 mcg/kg fentanyl. The time delay between propofol injection and the decrease in BIS index depends on the drug transition time (from the injection site to the effect site) and the index calculation time. Time delays between 14 and 155 seconds have been reported for the BIS index. In the study, the BIS index will be evaluated every 30 seconds. The initial dose and infusion rate will be applied as in Group O, with the target index in the BIS group being 40-60. An additional dose of 20 mg will be planned every 30 seconds until the target index is reached. In case of hypotension, the management of hypotension (vasopressor treatment, Trendelenburg position, fluid loading) is left to the discretion of the responsible anesthesiologist. At the end of the procedure, hemodynamic parameters (SAB, DAB, OAB, HR, SpO2), BIS values, time to reach BIS <60, Observer's Assessment of Alertness/Sedation Scale (OASS), anesthesia induction drug and doses, hypotension treatment, and airway equipment placement time will be recorded.

The sample size calculation was performed using MedCalc 15.8 (MedCalc Software bvba, Ostend, Belgium). It was determined that a minimum of 122 patients (61 + 61) is sufficient for P1 = 0.6, P2 = 0.3, α = 0.05, and a power of 90% (1-β).

Being tested
urological surgical intervention
Keywords
geriatric anesthesia, bispectral index monitor, hypotension
Medical subject headings
Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • urological surgical interventionProcedure or surgery

    Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.

Study groups in NCT06232980
Study groupRoleWhat they receive
Anesthesia induction group guided by BIS in geriatric patients.Active comparatorThe BIS index will be evaluated every 30 seconds. The initial dose and infusion rate will be applied as 1.5 mg/kg and 100 mg/min, respectively. In the BIS group, the target index is set between 40-60, and additional doses of 20 mg will be planned every 30 seconds until reaching this target index.
Receives: Procedure: urological surgical intervention
Observer's Alertness/Sedation Score-guided induction group in geriatric patients.Active comparatorThe initial dose will be applied as 1.5 mg/kg, and the infusion rate will be 100 mg/min. An additional 20 mg of propofol will be administered every 30 seconds until the Observer's Assessment of Alertness/Sedation (OAA/S) score reaches 1.
Receives: Procedure: urological surgical intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Use of BIS for preventing hypotension (mean arterial pressure (MAP) <60 mmHg) during propofol induction in geriatric patients

    Measured: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes.

Secondary outcomes (9)
  1. Find the differences between the input MAP and the MAP at each measurement

    Measured: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the differences between the entry MAP and the MAP at each measurement will be determined.

  2. Find the difference between input MAP and lowest MAP

    Measured: Mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the difference between the entry MAP and the lowest MAP will be determined.

  3. To determine the ratio of hypotensive and normotensive MAP measurements

    Measured: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the ratio of hypotensive to normotensive MAP measurements will be determined.

  4. To determine the number of patients with severe hypotension (MAP<50 mmHg)

    Measured: Mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the number of patients experiencing severe hypotension (MAP<50 mmHg) will be determined.

  5. To determine the number of patients receiving vasopressor therapy and the drug dosage

    Measured: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the number of patients developing hypotension receiving vasopressor therapy, along with the drug dosage, will be determined.

  6. To determine the number of patients who underwent Trendelenburg

    Measured: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the number of patients with hypotension who undergo Trendelenburg positioning will be determined.

  7. To determine the number of patients who developed tachycardia (HR>100/min)

    Measured: Heart rate will be recorded at 2-minute intervals for a duration of 14 minutes, and the number of patients developing tachycardia (heart rate >100 beats per minute) during this period will be determined.

  8. To determine the number of patients who developed hypertension (MAP>140)

    Measured: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes, and the number of patients developing hypertension (MAP >140 mmHg) will be determined.

  9. Finding the correlation between BIS values and MAP

    Measured: MAP, bispectral index, and the duration until the bispectral index reaches the range of 40-60 will be recorded at 2-minute intervals for a duration of 14 minutes. The correlation between bispectral index and MAP.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2024
  2. Study start1 Sep 2023
  3. Primary completion29 Mar 2024
  4. Study completion15 Apr 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Group O: HR, SAB, DAB, OAB, SpO2, and BIS values will be recorded at 2-minute intervals for 14 minutes. A standard initial dose of 1.5 mg/kg of propofol and an infusion rate of 100 mg/min will be applied. An additional 20 mg of propofol will be administered every 30 seconds until the Observer's Assessment of Alertness/Sedation (OAA/S) score reaches 1. Group B: HR, SAB, DAB, OAB, SpO2, and BIS values will be recorded at 2-minute intervals for 14 minutes. The BIS index will be evaluated every 30 seconds. The initial dose and infusion rate will be applied as in Group O, with the target index in the BIS group being 40-60. An additional dose of 20 mg will be planned every 30 seconds until the target index is reached.
Masking
Single blind
Who is masked
Participant
Enrolment
134 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06232980
Sponsor's protocol ID
UfukTakak1
Status last verified
Oct 2024
First submitted
10 Jan 2024
Last updated
26 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Devinney MJ, Berger M. Goldilocks and propofol dosage in older adults: Too much, too little, or just right? J Am Geriatr Soc. 2021 Aug;69(8):2106-2109. doi: 10.1111/jgs.17221. Epub 2021 May 8. No abstract available.

    PubMed 33964173
  • Rusch D, Arndt C, Eberhart L, Tappert S, Nageldick D, Wulf H. Bispectral index to guide induction of anesthesia: a randomized controlled study. BMC Anesthesiol. 2018 Jun 15;18(1):66. doi: 10.1186/s12871-018-0522-8.

    PubMed 29902969
  • Pilge S, Zanner R, Schneider G, Blum J, Kreuzer M, Kochs EF. Time delay of index calculation: analysis of cerebral state, bispectral, and narcotrend indices. Anesthesiology. 2006 Mar;104(3):488-94. doi: 10.1097/00000542-200603000-00016.

    PubMed 16508396
  • Gurses E, Sungurtekin H, Tomatir E, Dogan H. Assessing propofol induction of anesthesia dose using bispectral index analysis. Anesth Analg. 2004 Jan;98(1):128-131. doi: 10.1213/01.ANE.0000090314.43496.1D.

    PubMed 14693603
  • Schmidt GN, Bischoff P, Standl T, Lankenau G, Hilbert M, Schulte Am Esch J. Comparative evaluation of Narcotrend, Bispectral Index, and classical electroencephalographic variables during induction, maintenance, and emergence of a propofol/remifentanil anesthesia. Anesth Analg. 2004 May;98(5):1346-53, table of contents. doi: 10.1213/01.ane.0000111209.44119.30.

    PubMed 15105213
  • Chen L, Lu K, Luo T, Liang H, Gui Y, Jin S. Observer's Assessment of Alertness/Sedation-based titration reduces propofol consumption and incidence of hypotension during general anesthesia induction: A randomized controlled trial. Sci Prog. 2021 Oct;104(4):368504211052354. doi: 10.1177/00368504211052354.

    PubMed 34825617

Questions about this trial

What is this clinical trial studying?

A study testing urological surgical intervention in people with E03.155.253 and Bispectral Index Monitor, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Use of BIS for preventing hypotension (mean arterial pressure (MAP) <60 mmHg) during propofol induction in geriatric patients (time frame: The mean arterial pressure (MAP) will be recorded at 2-minute intervals for a duration of 14 minutes.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06232980, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in